At its September 24 EGM, Livzon shareholders approved a special interim dividend of RMB 10.20 per 10 shares. H-shareholders are due approximately HKD 11.85 per 10 H-shares, with payment scheduled for November 3.
At its September 24, 2026 meeting in Zhuhai, Livzon Pharmaceutical shareholders passed the sole resolution on the agenda. The resolution approved a special interim dividend of RMB 10.20 for every 10 shares. H-shareholders will receive approximately HKD 11.85 for every 10 H-shares.
The total dividend is RMB 905,665,314.42, including tax. It will go to holders of both A-shares and H-shares. The company has now set the amount and timetable.
Livzon set the total special interim dividend at RMB 905,665,314.42, including tax.
Holders and proxies represented 440,351,829 shares, about 49.6% of the company's share capital. Investors in both A-shares and H-shares took part. The resolution passed by poll. Livzon said no shareholders were required to abstain, and no one had declared an intention to oppose the resolution or abstain. The company's investor-relations update confirmed the resolution and the dividend rates for each share class.
No split was disclosed. The participation figure does not mean all shareholders supported the resolution, and the announcement does not give a vote breakdown.
For H-shares, October 13, 2026 is the last day to trade with the dividend entitlement. The shares go ex-dividend on October 14, and October 15 is the record date. The Hong Kong exchange filing says the H-share payment will be converted at HKD 1.00 to RMB 0.86054. The rate uses the People's Bank of China's average exchange rate on the approval date. A-shareholders will be paid in RMB and H-shareholders in HKD.
Livzon scheduled payment to H-shareholders for November 3, 2026. Industrial and Commercial Bank of China (Asia) Limited will act as paying agent in Hong Kong.
Livzon Pharmaceutical Group Inc. is a China-based drugmaker. It researches, develops, produces and sells drugs. Its A shares trade on the mainland market, while its H shares trade in Hong Kong. The meeting included holders of both share classes, but the announcement does not give separate participation or voting figures for either group.
A dividend returns cash to shareholders. It does not, on its own, show that earnings or cash generation will grow. Livzon's announcement gives no financial figures that would help assess whether future distributions are sustainable.
The latest analyst rating cited for HK:1513 is Sell, with a HK$22.99 price target. That is an analyst's view, not a guaranteed future price. The supplied information does not name the analyst or explain the reasoning behind the rating. Investors can consider the rating separately from the dividend approval.
A special distribution is not automatically comparable with a recurring quarterly payout. Another dividend analysis discusses that distinction. Livzon has announced the cash amount and payment schedule for its special interim dividend.
The approval authorizes a shareholder return, and the later disclosures set out the details investors need to track it. The dividend amount is set, and the H-share payment is scheduled. Neither fact alone determines whether the shares are attractive. Investors should assess the payout terms separately from the Sell rating and Livzon's broader investment outlook.
